VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Shijiazhuang No.4 Pharmaceutical (02005.HK): Safinamide Mesylate Approved as API for Marketed Preparations
Shijiazhuang No.4 Pharmaceutical (02005.HK): Safinamide Mesylate Approved as API for Marketed Preparations
May 26, 2026 07:54 CST Updated 08:17
Share:
